Effect of Disease Extent on Leucine‐Rich <scp>α2</scp> ‐Glycoprotein as a Marker for Endoscopic Mucosal Healing in Patients With Ulcerative Colitis
Our results support selecting biomarkers according to disease extent for the management of inflammatory bowel disease. In patients with UC and pancolitis, LRG is a viable alternative when fecal samples are not feasible. Conversely, for patients with left-sided colitis and proctitis, fecal markers with high diagnostic accuracy are recommended.
Authors
- Kei Onishi (ORCID: https://orcid.org/0009-0002-0976-2979)
- Kozue Kanemitsu‐Okada (ORCID: https://orcid.org/0009-0005-6488-9616)
- Shogo Kitahata (ORCID: https://orcid.org/0000-0003-2133-6569)
- Eiji Tsubouchi (ORCID: https://orcid.org/0009-0000-0669-4398)
- Kanako Kato
- Tomoe Kawamura (ORCID: https://orcid.org/0000-0001-6678-8724)
- Junko Matsuoka
- Fujimasa Tada (ORCID: https://orcid.org/0009-0007-3964-5876)
- Tomoyuki Ninomiya (ORCID: https://orcid.org/0000-0002-9949-0446)
- Ayaka Nakamura (ORCID: https://orcid.org/0009-0001-3743-8159)
- Hideko Ohama
- Yuka Kimura (ORCID: https://orcid.org/0009-0001-6392-6770)
- Taira Kuroda
- Atsushi Hiraoka
- Mai Saito
- Toru Usui
- Hideki Miyata
Institutions
- Ehime Prefectural Central Hospital (JP)
- Ehime University (JP)
Publication Details
- Journal
- JGH Open
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/jgh3.70341
- Primary Topic
- Clusterin in disease pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00